Asp-PSC: Effect of Aspirin on Reducing Cancer & Mortality in Primary Sclerosing Cholangitis

This study is a multicentre, double-blind, randomised placebo-controlled trial including patients with Primary Sclerosing Cholangitis who have a concurrent diagnosis of inflammatory bowel disease (IBD) and are at least 12 months post diagnosis. 968 patients will be randomised 2:1 Aspirin vs Placebo. Accrual will be over five years, with a minimum participant follow up of five years.

Patients will be seen at screening/baseline, month one and then six monthly (five months after month one, six monthly thereafter) in alignment with routine clinical care.